Results 51 to 60 of about 10,116 (169)
Obesity Reviews, EarlyView.ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao +4 more
wiley +1 more source
International Journal of Preventive Medicine, 2015 Background: Drug-drug interactions (DDIs) are an emerging threat to public health and are difficult to detect. To prevent DDIs and their burden, the possible DDIs should be kept in mind.
Marjan Emzhik +4 more
doaj +1 more source
BMC Endocrine Disorders, 2023 Background Childhood obesity is one of the main concerns of public health. Considering its long-term adverse health effect, various studies investigated the effect of drug therapy on anthropometric parameters and provided mixed results.
Zeinab Nikniaz +4 more
doaj +1 more source
eFood, Volume 7, Issue 2, April 2026.By integrating bioaffinity ultrafiltration coupled with HPLC‐MS/MS, this study identified quercetin, myricetrin, dihydromyricetin, and taxifolin from Ampelopsis grossedentata as key inhibitors of α‐glucosidase, pancreatic lipase, and xanthine oxidase, highlighting the promising potential of A.
Siyang Mao +5 more
wiley +1 more source
Endocrine and Metabolic ScienceBackground: Orlistat, a weight loss medication, is often less effective due to poor adherence to the dietary and exercise recommendations. However, its effectiveness is often compromised by poor adherence to recommended lifestyle changes and side effects
Khin Maung Win +5 more
doaj +1 more source
Effect of orlistat on obese women with polycystic ovary syndrome
Journal of Bio-X Research, 2018 . Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations.
Qi Jiang, Yuhua Shi
doaj +1 more source
Obesity Science &Practice, Volume 12, Issue 2, April 2026.ABSTRACT Objective In general practice settings, the weight‐loss effectiveness of glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) is often lower than in clinical efficacy trials. Little is known about whether this may be due, in part, to clinicians' knowledge about obesity medicine and the nature of clinic visits (e.g., weight‐focused vs. general
Dina H. Griauzde +15 more
wiley +1 more source
Food & Nutrition Research, 2015 Background: Obesity and overweight are major public health problems. Various factors, such as daily nutritional habits, physical inactivity, and genetic, are related to the prevalence of obesity. Recently, it was revealed that the gut microflora may also
Golgis Karimi +7 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2627-2641, April 2026.Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay +19 more
wiley +1 more source
Evaluation of efficacy and safety of orlistat in obese patients
Indian Journal of Endocrinology and Metabolism, 2011 Context: Rapidly rising prevalence of obesity is alarming. Obesity predisposes to co-morbidities like hypertension, type 2 diabetes mellitus, dyslipidemias, thus substantially rising healthcare expenditure. Lifestyle modifications alone have very limited
Suyog S Jain +5 more
doaj +1 more source